Vaccine development for emerging infectious diseases
Examination of the vaccine strategies and technical platforms used for the COVID-19 pandemic in the context of those used for previous emerging and reemerging infectious diseases and pandemics may offer some mutually beneficial lessons. The unprecedented scale and rapidity of dissemination of recent...
Gespeichert in:
| Veröffentlicht in: | Nature medicine 2021-04, Vol.27 (4), p.591-600 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 600 |
|---|---|
| container_issue | 4 |
| container_start_page | 591 |
| container_title | Nature medicine |
| container_volume | 27 |
| creator | Excler, Jean-Louis Saville, Melanie Berkley, Seth Kim, Jerome H. |
| description | Examination of the vaccine strategies and technical platforms used for the COVID-19 pandemic in the context of those used for previous emerging and reemerging infectious diseases and pandemics may offer some mutually beneficial lessons. The unprecedented scale and rapidity of dissemination of recent emerging infectious diseases pose new challenges for vaccine developers, regulators, health authorities and political constituencies. Vaccine manufacturing and distribution are complex and challenging. While speed is essential, clinical development to emergency use authorization and licensure, pharmacovigilance of vaccine safety and surveillance of virus variants are also critical. Access to vaccines and vaccination needs to be prioritized in low- and middle-income countries. The combination of these factors will weigh heavily on the ultimate success of efforts to bring the current and any future emerging infectious disease pandemics to a close.
Examination of the vaccine strategies and technical platforms used for the COVID-19 pandemic in the context of those used for previous emerging and reemerging infectious diseases and pandemics can offer critical lessons to prepare for future public health emergencies. |
| doi_str_mv | 10.1038/s41591-021-01301-0 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2512334085</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A658607783</galeid><sourcerecordid>A658607783</sourcerecordid><originalsourceid>FETCH-LOGICAL-c623t-b67fb71c67b1a56ccee897644034cdbbb46ada2199f61f7c82d799166003f80b3</originalsourceid><addsrcrecordid>eNqN0m1r1TAUB_AgDjenX8AXUhCGvuhMmjQPL8fwYTAY-DB8F9L0pMtok2vSin57c717unIRKW1K-zuH0-aP0AuCjwmm8m1mpFWkxk05CcXl-ggdkJbxmgj87XG5x0LWUrV8Hz3N-RpjTHGrnqB9SiXjnJADxC6NtT5A1cMPGONqgjBXLqYKJkiDD0PlgwM7-7jkqvcZTIb8DO05M2Z4frMeoq_v3305_VifX3w4Oz05ry1v6Fx3XLhOEMtFR0zLrQWQSnDGMGW277qOcdObhijlOHHCyqYXShHOy5xO4o4eotebvqsUvy-QZz35bGEcTYAyj25a0lDKsGwLffUXvY5LCmW6taJYNYyqezWYEXT5sjgnY9dN9QlvJcdCSFpUvUMNECCZMQZwvjze8sc7fDl6mLzdWfBmq6CYGX7Og1ly1mefP_2_vbjctkcP7BWYcb7KcVzK7oW8DZsNtCnmnMDpVfKTSb80wXqdLb3Jli7Z0n-ypXEpennzi5dugv6u5DZMBdANyOVVGCDd78E_2v4G4hDTcQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2513092439</pqid></control><display><type>article</type><title>Vaccine development for emerging infectious diseases</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Nature Journals Online</source><creator>Excler, Jean-Louis ; Saville, Melanie ; Berkley, Seth ; Kim, Jerome H.</creator><creatorcontrib>Excler, Jean-Louis ; Saville, Melanie ; Berkley, Seth ; Kim, Jerome H.</creatorcontrib><description>Examination of the vaccine strategies and technical platforms used for the COVID-19 pandemic in the context of those used for previous emerging and reemerging infectious diseases and pandemics may offer some mutually beneficial lessons. The unprecedented scale and rapidity of dissemination of recent emerging infectious diseases pose new challenges for vaccine developers, regulators, health authorities and political constituencies. Vaccine manufacturing and distribution are complex and challenging. While speed is essential, clinical development to emergency use authorization and licensure, pharmacovigilance of vaccine safety and surveillance of virus variants are also critical. Access to vaccines and vaccination needs to be prioritized in low- and middle-income countries. The combination of these factors will weigh heavily on the ultimate success of efforts to bring the current and any future emerging infectious disease pandemics to a close.
Examination of the vaccine strategies and technical platforms used for the COVID-19 pandemic in the context of those used for previous emerging and reemerging infectious diseases and pandemics can offer critical lessons to prepare for future public health emergencies.</description><identifier>ISSN: 1078-8956</identifier><identifier>EISSN: 1546-170X</identifier><identifier>DOI: 10.1038/s41591-021-01301-0</identifier><identifier>PMID: 33846611</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>631/250/590 ; 692/699/255/2514 ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Cholera Vaccines - immunology ; Communicable Diseases, Emerging - epidemiology ; Communicable Diseases, Emerging - prevention & control ; Context ; Coronaviruses ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - immunology ; Dengue Vaccines - immunology ; Emerging communicable diseases ; Epidemics ; Health Services Accessibility ; Humans ; Infectious Diseases ; Metabolic Diseases ; Molecular Medicine ; Neurosciences ; Pandemics ; Pharmaceutical research ; Pharmacovigilance ; Platforms ; Prevention ; Public health ; Regulators ; Review Article ; SARS-CoV-2 - immunology ; South Korea ; Typhoid-Paratyphoid Vaccines - immunology ; Vaccine development ; Vaccines ; Vaccines - immunology ; Viral diseases ; Yellow Fever Vaccine - immunology</subject><ispartof>Nature medicine, 2021-04, Vol.27 (4), p.591-600</ispartof><rights>The Author(s), under exclusive licence to Springer Nature America, Inc. 2021</rights><rights>COPYRIGHT 2021 Nature Publishing Group</rights><rights>The Author(s), under exclusive licence to Springer Nature America, Inc. 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c623t-b67fb71c67b1a56ccee897644034cdbbb46ada2199f61f7c82d799166003f80b3</citedby><cites>FETCH-LOGICAL-c623t-b67fb71c67b1a56ccee897644034cdbbb46ada2199f61f7c82d799166003f80b3</cites><orcidid>0000-0002-6462-5101 ; 0000-0003-0461-6438</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41591-021-01301-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41591-021-01301-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33846611$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Excler, Jean-Louis</creatorcontrib><creatorcontrib>Saville, Melanie</creatorcontrib><creatorcontrib>Berkley, Seth</creatorcontrib><creatorcontrib>Kim, Jerome H.</creatorcontrib><title>Vaccine development for emerging infectious diseases</title><title>Nature medicine</title><addtitle>Nat Med</addtitle><addtitle>Nat Med</addtitle><description>Examination of the vaccine strategies and technical platforms used for the COVID-19 pandemic in the context of those used for previous emerging and reemerging infectious diseases and pandemics may offer some mutually beneficial lessons. The unprecedented scale and rapidity of dissemination of recent emerging infectious diseases pose new challenges for vaccine developers, regulators, health authorities and political constituencies. Vaccine manufacturing and distribution are complex and challenging. While speed is essential, clinical development to emergency use authorization and licensure, pharmacovigilance of vaccine safety and surveillance of virus variants are also critical. Access to vaccines and vaccination needs to be prioritized in low- and middle-income countries. The combination of these factors will weigh heavily on the ultimate success of efforts to bring the current and any future emerging infectious disease pandemics to a close.
Examination of the vaccine strategies and technical platforms used for the COVID-19 pandemic in the context of those used for previous emerging and reemerging infectious diseases and pandemics can offer critical lessons to prepare for future public health emergencies.</description><subject>631/250/590</subject><subject>692/699/255/2514</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Cholera Vaccines - immunology</subject><subject>Communicable Diseases, Emerging - epidemiology</subject><subject>Communicable Diseases, Emerging - prevention & control</subject><subject>Context</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 vaccines</subject><subject>COVID-19 Vaccines - immunology</subject><subject>Dengue Vaccines - immunology</subject><subject>Emerging communicable diseases</subject><subject>Epidemics</subject><subject>Health Services Accessibility</subject><subject>Humans</subject><subject>Infectious Diseases</subject><subject>Metabolic Diseases</subject><subject>Molecular Medicine</subject><subject>Neurosciences</subject><subject>Pandemics</subject><subject>Pharmaceutical research</subject><subject>Pharmacovigilance</subject><subject>Platforms</subject><subject>Prevention</subject><subject>Public health</subject><subject>Regulators</subject><subject>Review Article</subject><subject>SARS-CoV-2 - immunology</subject><subject>South Korea</subject><subject>Typhoid-Paratyphoid Vaccines - immunology</subject><subject>Vaccine development</subject><subject>Vaccines</subject><subject>Vaccines - immunology</subject><subject>Viral diseases</subject><subject>Yellow Fever Vaccine - immunology</subject><issn>1078-8956</issn><issn>1546-170X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqN0m1r1TAUB_AgDjenX8AXUhCGvuhMmjQPL8fwYTAY-DB8F9L0pMtok2vSin57c717unIRKW1K-zuH0-aP0AuCjwmm8m1mpFWkxk05CcXl-ggdkJbxmgj87XG5x0LWUrV8Hz3N-RpjTHGrnqB9SiXjnJADxC6NtT5A1cMPGONqgjBXLqYKJkiDD0PlgwM7-7jkqvcZTIb8DO05M2Z4frMeoq_v3305_VifX3w4Oz05ry1v6Fx3XLhOEMtFR0zLrQWQSnDGMGW277qOcdObhijlOHHCyqYXShHOy5xO4o4eotebvqsUvy-QZz35bGEcTYAyj25a0lDKsGwLffUXvY5LCmW6taJYNYyqezWYEXT5sjgnY9dN9QlvJcdCSFpUvUMNECCZMQZwvjze8sc7fDl6mLzdWfBmq6CYGX7Og1ly1mefP_2_vbjctkcP7BWYcb7KcVzK7oW8DZsNtCnmnMDpVfKTSb80wXqdLb3Jli7Z0n-ypXEpennzi5dugv6u5DZMBdANyOVVGCDd78E_2v4G4hDTcQ</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Excler, Jean-Louis</creator><creator>Saville, Melanie</creator><creator>Berkley, Seth</creator><creator>Kim, Jerome H.</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6462-5101</orcidid><orcidid>https://orcid.org/0000-0003-0461-6438</orcidid></search><sort><creationdate>20210401</creationdate><title>Vaccine development for emerging infectious diseases</title><author>Excler, Jean-Louis ; Saville, Melanie ; Berkley, Seth ; Kim, Jerome H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c623t-b67fb71c67b1a56ccee897644034cdbbb46ada2199f61f7c82d799166003f80b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>631/250/590</topic><topic>692/699/255/2514</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Cholera Vaccines - immunology</topic><topic>Communicable Diseases, Emerging - epidemiology</topic><topic>Communicable Diseases, Emerging - prevention & control</topic><topic>Context</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 vaccines</topic><topic>COVID-19 Vaccines - immunology</topic><topic>Dengue Vaccines - immunology</topic><topic>Emerging communicable diseases</topic><topic>Epidemics</topic><topic>Health Services Accessibility</topic><topic>Humans</topic><topic>Infectious Diseases</topic><topic>Metabolic Diseases</topic><topic>Molecular Medicine</topic><topic>Neurosciences</topic><topic>Pandemics</topic><topic>Pharmaceutical research</topic><topic>Pharmacovigilance</topic><topic>Platforms</topic><topic>Prevention</topic><topic>Public health</topic><topic>Regulators</topic><topic>Review Article</topic><topic>SARS-CoV-2 - immunology</topic><topic>South Korea</topic><topic>Typhoid-Paratyphoid Vaccines - immunology</topic><topic>Vaccine development</topic><topic>Vaccines</topic><topic>Vaccines - immunology</topic><topic>Viral diseases</topic><topic>Yellow Fever Vaccine - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Excler, Jean-Louis</creatorcontrib><creatorcontrib>Saville, Melanie</creatorcontrib><creatorcontrib>Berkley, Seth</creatorcontrib><creatorcontrib>Kim, Jerome H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nature medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Excler, Jean-Louis</au><au>Saville, Melanie</au><au>Berkley, Seth</au><au>Kim, Jerome H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vaccine development for emerging infectious diseases</atitle><jtitle>Nature medicine</jtitle><stitle>Nat Med</stitle><addtitle>Nat Med</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>27</volume><issue>4</issue><spage>591</spage><epage>600</epage><pages>591-600</pages><issn>1078-8956</issn><eissn>1546-170X</eissn><abstract>Examination of the vaccine strategies and technical platforms used for the COVID-19 pandemic in the context of those used for previous emerging and reemerging infectious diseases and pandemics may offer some mutually beneficial lessons. The unprecedented scale and rapidity of dissemination of recent emerging infectious diseases pose new challenges for vaccine developers, regulators, health authorities and political constituencies. Vaccine manufacturing and distribution are complex and challenging. While speed is essential, clinical development to emergency use authorization and licensure, pharmacovigilance of vaccine safety and surveillance of virus variants are also critical. Access to vaccines and vaccination needs to be prioritized in low- and middle-income countries. The combination of these factors will weigh heavily on the ultimate success of efforts to bring the current and any future emerging infectious disease pandemics to a close.
Examination of the vaccine strategies and technical platforms used for the COVID-19 pandemic in the context of those used for previous emerging and reemerging infectious diseases and pandemics can offer critical lessons to prepare for future public health emergencies.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>33846611</pmid><doi>10.1038/s41591-021-01301-0</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-6462-5101</orcidid><orcidid>https://orcid.org/0000-0003-0461-6438</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-8956 |
| ispartof | Nature medicine, 2021-04, Vol.27 (4), p.591-600 |
| issn | 1078-8956 1546-170X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2512334085 |
| source | MEDLINE; SpringerLink Journals; Nature Journals Online |
| subjects | 631/250/590 692/699/255/2514 Biomedical and Life Sciences Biomedicine Cancer Research Cholera Vaccines - immunology Communicable Diseases, Emerging - epidemiology Communicable Diseases, Emerging - prevention & control Context Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - immunology Dengue Vaccines - immunology Emerging communicable diseases Epidemics Health Services Accessibility Humans Infectious Diseases Metabolic Diseases Molecular Medicine Neurosciences Pandemics Pharmaceutical research Pharmacovigilance Platforms Prevention Public health Regulators Review Article SARS-CoV-2 - immunology South Korea Typhoid-Paratyphoid Vaccines - immunology Vaccine development Vaccines Vaccines - immunology Viral diseases Yellow Fever Vaccine - immunology |
| title | Vaccine development for emerging infectious diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T05%3A42%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vaccine%20development%20for%20emerging%20infectious%20diseases&rft.jtitle=Nature%20medicine&rft.au=Excler,%20Jean-Louis&rft.date=2021-04-01&rft.volume=27&rft.issue=4&rft.spage=591&rft.epage=600&rft.pages=591-600&rft.issn=1078-8956&rft.eissn=1546-170X&rft_id=info:doi/10.1038/s41591-021-01301-0&rft_dat=%3Cgale_proqu%3EA658607783%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2513092439&rft_id=info:pmid/33846611&rft_galeid=A658607783&rfr_iscdi=true |